US EditionNovo Nordisk shares plunge 15% after Wegovy-maker cuts full-year guidance
DENMARK, JUL 29 – Novo Nordisk cut 2025 sales growth forecast to 8%-14% due to competition and persistent use of compounded drugs affecting Wegovy and Ozempic in the U.S. market.
- On Tuesday, Danish pharmaceutical firm Novo Nordisk lowered its sales and profit forecasts for the full year, attributing the revision to softer growth expectations in the U.S. market.
- The downgrade followed slower-than-expected expansion and persistent use of compounded GLP-1s affecting Wegovy sales, as well as increased competition in the U.S.
- Novo Nordisk lowered its outlook primarily due to reduced expectations for U.S. sales growth in the latter half of the year for both its obesity treatment Wegovy and diabetes medication Ozempic.
- The company has lowered its forecast for annual sales growth to a range of 8% to 14%, down from the previous projection of 13% to 21%, and reduced its expected operating profit increase to between 10% and 16%, compared to an earlier estimate of 16% to 24%; meanwhile, shares dropped 17% as of 12:30 p.m. London time.
- This guidance cut signals reduced expectations for Novo Nordisk's key products in the U.S. market and reflects challenges in weight loss and diabetes treatment growth.
52 Articles
52 Articles
A number of banks have lowered their price targets for Novo Nordisk's shares since Tuesday, when the company lowered its growth expectations for the year. A price target is a bank's or analyst's expectation for...
Novo Nordisk has lowered its annual forecast for the second time this year, and its shares have fallen significantly on the news.
For the second time this year, pharmaceutical giant Novo Nordisk is downgrading its growth expectations for 2025. Copying of weight loss drugs is plaguing the company.
Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?
Key Points in This Article: Novo Nordisk’s (NVO) operations update reported 18% sales and 29% operating profit growth for H1 2025, but one-off adjustments inflated results. A slashed 2025 outlook cites weaker Wegovy and Ozempic growth, compounded GLP-1 competition, and CagriSema trial failures. Illegal compounding persists despite FDA action, undermining sales, with a failed Hims & Hers partnership exposing regulatory challenges. Nvidia made…
Coverage Details
Bias Distribution
- 45% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
